Reuters logo
BRIEF-Theraclion and co-lead investigator discuss clinical trial combining echotherapy and imunotherapy to treat metastatic breast cancer
September 11, 2017 / 7:00 AM / 11 days ago

BRIEF-Theraclion and co-lead investigator discuss clinical trial combining echotherapy and imunotherapy to treat metastatic breast cancer

Sept 11 (Reuters) - THERACLION SA:

* THERACLION AND CO-LEAD INVESTIGATOR DISCUSS RATIONALE AND DESIGN OF FIRST CLINICAL TRIAL COMBINING ECHOTHERAPY AND IMUNOTHERAPY TO TREAT METASTATIC BREAST CANCER

* CLINICAL TRIAL IS EXPECTED TO BEGIN PATIENT ACCRUAL AT UVA IN OCTOBER 2017, AND WILL BE A TWO-ARM STUDY OF 12 PATIENTS

* CLINICAL TRIAL WILL BE A TWO-ARM STUDY OF 12 PATIENTS

* ‍PEMBROLIZUMAB IS ABLE TO INDUCE AN IMMUNE RESPONSE TO SOME BREAST CANCERS AND HIFU ARE ABLE TO INDUCE AN IMMUNE RESPONSE IN MOST TUMORS, BUT NOT ENOUGH ON ITS OWN TO BE CURATIVE​

* ‍RATIONALE FOR CLINICAL STUDY IS THAT COMBINATION OF PEMBROLIZUMAB AND HIFU MIGHT BE MORE EFFECTIVE​

* ‍PRIMARY OBJECTIVES ARE TO ASSESS ADVERSE EVENT PROFILE OF PEMBROLIZUMAB AND FOCUSED ULTRASOUND THERAPY

* ‍PRIMARY OBJECTIVES ARE TO DETERMINE OF ADDITION OF PEMBROLIZUMAB TO FOCUSED ULTRASOUND INCREASES PROPORTION OF CD8+ TUMOR INFILTRATING LYMPHOCYTES IN PRIMARY ABLATION ZONE​

* ‍SECONDARY OBJECTIVES ARE TO COMPARE CD8+ T-CELL RESPONSES AT PERI-ABLATION ZONES WHEN PEMBROLIZUMAB IS GIVEN BEFORE OR AFTER HIFU​

* ‍SECONDARY OBJECTIVES ARE TO EVALUATE PROGRESSION FREE AND OVERALL SURVIVAL​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below